nach oben

30.11.2019 | Original Article

Interleukin-38 in colorectal cancer: a potential role in precision medicine

verfasst von: Feier Chen, Feng Zhang, Zhenyu Tan, Brett D. Hambly, Shisan Bao, Kun Tao

Erschienen in: Cancer Immunology, Immunotherapy

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related death, partly due to a lack of reliable biomarkers for early diagnosis. To improve the outcome of CRC, it is critical to provide diagnosis at an early stage using promising sensitive/specific marker(s). Using immunohistochemistry and histopathology, IL-38 expression was determined in tissue arrays of CRC with different TNM status and depth of tumour invasion. Data were compared to IL-38 in adjacent non-cancer tissue and correlated with demographic information, including survival. A substantial reduction of IL-38 was detected in the CRC tissue compared to adjacent non-cancer colonic tissue. IL-38 correlated with the extent of tumour differentiation (P < 0.0001); CRC location in the left side of the colon (P < 0.05), and smaller tumour size (≤ 5 cm; P < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated both high specificity and high sensitivity of IL-38 for the diagnosis of CRC [area under the curve (AUC) = 0.89)]. By sub-group analysis, AUC of IL-38 for the diagnosis of CRC was higher in poorly differentiated, right-sided CRC or tumour size > 5 cm (all AUC > 0.9). Significantly, longer survival was observed for the IL-38^high versus the IL-38^low groups in CRC patients (P = 0.04). Survival was also longer for IL-38^high patients with lymph node metastasis (P = 0.01) and TNM stage III-IV (P = 0.02). Multivariate analysis demonstrated that IL-38 (P = 0.05) and tumour invasion depth (P = 0.04) were independent factors for survival. High IL38 in CRC is an independent prognostic factor for the longer survival of CRC patients. IL-38 signalling may constitute a therapeutic target in CRC.

Nur mit Berechtigung zugänglich

Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC (1994) A prospective study of family history and the risk of colorectal cancer. N Engl J Med 331(25):1669–1674. https://doi.org/10.1056/NEJM199412223312501 CrossRefPubMed

Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics. CA Cancer J Clin 64(2):104–117. https://doi.org/10.3322/caac.21220 CrossRefPubMed

Welch HG, Robertson DJ (2016) Colorectal cancer on the decline-why screening can’t explain it all. N Engl J Med 374(17):1605–1607. https://doi.org/10.1056/NEJMp1600448 CrossRefPubMed

Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https://doi.org/10.3389/fonc.2018.00086 CrossRefPubMedPubMedCentral

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(4):268. https://doi.org/10.1038/nrc.2017.24 CrossRefPubMed

De Robertis M, Poeta ML, Signori E, Fazio VM (2018) Current understanding and clinical utility of miRNAs regulation of colon cancer stem cells. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2018.08.008 CrossRefPubMed

Mager LF, Wasmer MH, Rau TT, Krebs P (2016) Cytokine-induced modulation of colorectal cancer. Front Oncol 6:96. https://doi.org/10.3389/fonc.2016.00096 CrossRefPubMedPubMedCentral

Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O’Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, Kelk P, van de Veerdonk F, Gabel C (2010) IL-1 family nomenclature. Nat Immunol 11(11):973. https://doi.org/10.1038/ni1110-973 CrossRefPubMedPubMedCentral

Takeuchi Y, Seki T, Kobayashi N, Sano K, Shigemura T, Shimojo H, Matsumoto K, Agematsu K (2018) Analysis of serum IL-38 in juvenile-onset systemic lupus erythematosus. Mod Rheumatol. https://doi.org/10.1080/14397595.2018.1436118 CrossRefPubMed

10.

Yu Z, Liu J, Zhang R, Huang X, Sun T, Wu Y, Hambly BD, Bao S (2017) IL-37 and 38 signalling in gestational diabetes. J Reprod Immunol 124:8–14. https://doi.org/10.1016/j.jri.2017.09.011 CrossRefPubMed

11.

Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S, Katsura M, Toyokawa G, Shoji F, Okamoto M, Oda Y, Hoshino T, Maehara Y (2017) Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: possible association with PD-L1 expression. PLoS One 12(7):e0181598. https://doi.org/10.1371/journal.pone.0181598 CrossRefPubMedPubMedCentral

12.

Novellasdemunt L, Antas P, Li VS (2015) Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell Physiol 309(8):C511–C521. https://doi.org/10.1152/ajpcell.00117.2015 CrossRefPubMedPubMedCentral

13.

Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN (2000) Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26(2):146–147. https://doi.org/10.1038/79859 CrossRefPubMed

14.

Chen L, Zhu C, Li F, Wang Y, Bao R, Cao Z, Xiang X, Yan L, Lin L, Zhao G, Xie Q, Bao S, Wang H (2018) Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. Cell Biosci 8:14. https://doi.org/10.1186/s13578-018-0215-5 CrossRefPubMedPubMedCentral

15.

Zhou T, Sun Y, Li M, Ding Y, Yin R, Li Z, Xie Q, Bao S, Cai W (2018) Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway. Cell Death Dis 9(6):590. https://doi.org/10.1038/s41419-018-0670-2 CrossRefPubMedPubMedCentral

16.

Chami B, Yeung A, Buckland M, Liu H, Fong GM, Tao K, Bao S (2017) CXCR3 plays a critical role for host protection against Salmonellosis. Sci Rep 7(1):10181. https://doi.org/10.1038/s41598-017-09150-z CrossRefPubMedPubMedCentral

17.

Cao Z, Li Z, Wang H, Liu Y, Xu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Cai W, Liu L, Bao S, Xie Q (2017) Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int 37(11):1612–1621. https://doi.org/10.1111/liv.13536 CrossRefPubMed

18.

Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, Katsurada Y, Nakamura T, Mochizuki H, Yamamoto J, Hase K (2012) New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 36(2):193–201. https://doi.org/10.1097/PAS.0b013e318235edee CrossRefPubMed

19.

Chen CH, Hsieh MC, Hsiao PK, Lin EK, Lu YJ, Wu SY (2017) A critical reappraisal for the value of tumor size as a prognostic variable in rectal adenocarcinoma. J Cancer 8(10):1927–1934. https://doi.org/10.7150/jca.17930 CrossRefPubMedPubMedCentral

20.

Ghidini M, Petrelli F, Tomasello G (2018) Right versus left colon cancer: resectable and metastatic disease. Curr Treat Options Oncol 19(6):31. https://doi.org/10.1007/s11864-018-0544-y CrossRefPubMed

21.

Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383(9927):1490–1502. https://doi.org/10.1016/S0140-6736(13)61649-9 CrossRefPubMed

22.

van de Veerdonk FL, de Graaf DM, Joosten LA, Dinarello CA (2018) Biology of IL-38 and its role in disease. Immunol Rev 281(1):191–196. https://doi.org/10.1111/imr.12612 CrossRefPubMed

23.

Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140(6):1807–1816. https://doi.org/10.1053/j.gastro.2011.01.057 CrossRefPubMed

24.

Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13(11):759–771. https://doi.org/10.1038/nrc3611 CrossRefPubMed

25.

Takenaka SI, Kaieda S, Kawayama T, Matsuoka M, Kaku Y, Kinoshita T, Sakazaki Y, Okamoto M, Tominaga M, Kanesaki K, Chiba A, Miyake S, Ida H, Hoshino T (2015) IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Rep 4:386–391. https://doi.org/10.1016/j.bbrep.2015.10.015 CrossRefPubMedPubMedCentral

26.

Rudloff I, Godsell J, Nold-Petry CA, Harris J, Hoi A, Morand EF, Nold MF (2015) Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 67(12):3219–3225. https://doi.org/10.1002/art.39328 CrossRefPubMed

27.

Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, Raimondo S, Carubbi F, Valesini G, Giacomelli R, Rizzo A, Triolo G (2015) Interleukin-36alpha axis is modulated in patients with primary Sjogren’s syndrome. Clin Exp Immunol 181(2):230–238. https://doi.org/10.1111/cei.12644 CrossRefPubMedPubMedCentral

28.

Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, Vigne S, Gabay C, Palmer G, Le Goff B, Blanchard F (2016) Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol 184(2):159–173. https://doi.org/10.1111/cei.12761 CrossRefPubMed

29.

Ummarino D (2017) Experimental arthritis: IL-38 promotes anti-inflammatory effects. Nat Rev Rheumatol 13(5):260. https://doi.org/10.1038/nrrheum.2017.55 CrossRefPubMed

30.

Grivennikov SI (2013) Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35(2):229–244. https://doi.org/10.1007/s00281-012-0352-6 CrossRefPubMed

31.

Catalan-Dibene J, McIntyre LL, Zlotnik A (2018) Interleukin 30 to interleukin 40. J Interferon Cytokine Res 38(10):423–439. https://doi.org/10.1089/jir.2018.0089 CrossRefPubMedPubMedCentral

32.

Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E, Olleros ML, Vesin D, Garcia I, Ronchi F, Sallusto F, Sims JE, Gabay C (2012) IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4 + T cells. Blood 120(17):3478–3487. https://doi.org/10.1182/blood-2012-06-439026 CrossRefPubMed

33.

Lee MS, Menter DG, Kopetz S (2017) Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw 15(3):411–419CrossRef

34.

Venook AP (2017) Right-sided vs left-sided colorectal cancer. Clin Adv Hematol Oncol 15(1):22–24PubMed

35.

Kato T, Alonso S, Muto Y, Perucho M, Rikiyama T (2016) Tumor size is an independent risk predictor for metachronous colorectal cancer. Oncotarget 7(14):17896–17904. https://doi.org/10.18632/oncotarget.7555 CrossRefPubMedPubMedCentral

36.

Saha S, Kanaan MN, Shaik M, Abadeer B, Korant A, Krishnamoorthy M, Kaushal S, Singh TT, Arora ML, Wiese D (2013) Tumor size as a prognostic factor for patients with colon cancer undergoing sentinel lymph node mapping and conventional surgery. J Clin Oncol. https://doi.org/10.1200/jco.2013.31.4_suppl.546 CrossRef

37.

Marsland BJ, Trompette A, Gollwitzer ES (2015) The gut-lung axis in respiratory disease. Ann Am Thorac Soc 12(Suppl 2):S150–S156. https://doi.org/10.1513/AnnalsATS.201503-133AW CrossRefPubMed

38.

Lin JH, Giovannucci E (2010) Sex hormones and colorectal cancer: what have we learned so far? J Natl Cancer Inst 102(23):1746–1747. https://doi.org/10.1093/jnci/djq444 CrossRefPubMedPubMedCentral

39.

Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, Sheahan K (2016) Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 115(7):831–840. https://doi.org/10.1038/bjc.2016.274 CrossRefPubMedPubMedCentral

Titel: Interleukin-38 in colorectal cancer: a potential role in precision medicine
verfasst von: Feier Chen
Feng Zhang
Zhenyu Tan
Brett D. Hambly
Shisan Bao
Kun Tao
Publikationsdatum: 30.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02440-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Interleukin-38 in colorectal cancer: a potential role in precision medicine

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie